Get the Stockscreener App
6.82
0.87%
-0.06
After Hours:
6.60
-0.22
-3.23%
Champions Oncology Inc stock is traded at $6.82, with a volume of 3,120.
It is down -0.87% in the last 24 hours and up +10.00% over the past month.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
See More
Previous Close:
$6.88
Open:
$6.73
24h Volume:
3,120
Relative Volume:
0.34
Market Cap:
$94.71M
Revenue:
$57.94M
Net Income/Loss:
$-2.34M
P/E Ratio:
-40.94
EPS:
-0.1666
Net Cash Flow:
$3.82M
1W Performance:
+19.23%
1M Performance:
+10.00%
6M Performance:
+7.91%
1Y Performance:
-15.28%
1-Day Range:
$6.51
$6.82
1-Week Range:
$5.71
$7.00
52-Week Range:
$5.50
$9.6299
Champions Oncology Inc Stock (CSBR) Company Profile
Name
Champions Oncology Inc
Sector
Industry
Phone
410-369-0365
Address
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
6.82 | 88.04M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-18-19 | Initiated | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Stock (CSBR) Latest News
Hong Kong IPO Boom Faces Performance Challenges as Post-Listing Returns FadeEarnings Weakness Phase - newsline.com
As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation? (LLY:NYSE) - Seeking Alpha
(CSBR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Check For Cancer Champion Dr. Ryan Schoenfeld Has a Vision For Earlier Detection - ACCESS Newswire
Check for Cancer Champion Dr. Ryan Schoenfeld has a vision for earlier detection - Aflac Newsroom
Vail Resorts (MTN) Edges Higher as Ski Season Momentum BuildsModified Schiff - newsline.com
AQU PE Ratio & Valuation, Is AQU Overvalued - Intellectia AI
CSBR Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock Edges HigherBook Value Growth - newsline.com
CSBR Q1 2026 Earnings: Earnings Miss Hides Underlying Progress in Oncology PlatformCFO Commentary Report - newsline.com
Champions Oncology Q1 2026 Earnings: EPS Miss of 121.79% Weighs on Results Despite Modest Stock Gain - newsline.com
CGI Inc. (GIB) Faces Pressure: Stock Drops Nearly 4% as Support Levels ApproachPre-Earnings Momentum - newsline.com
CSBR Technical Analysis & Stock Price Forecast - Intellectia AI
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer - Yahoo Finance UK
FedEx Invests $54 Million in Netherlands Truck Hub to Support Air Freight IntegrationProfit Guidance Range - newsline.com
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
(CSBR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Medidata Champions Collaborative Scientific Advancement at ASCO with New Research on Oncology Protocol Optimization and CAR T Efficacy - marketscreener.com
Champions Oncology Inc. (CSBR) Q1 2026 Earnings: Earnings Miss Estimates as EPS Falls to -$0.02Special Dividend Alert - The Legal Advocate
Apple’s AI Roadmap Faces Pivotal Test at Upcoming WWDCRevenue Recognition Risk - The Legal Advocate
Explore US Stocks on MEXC: Your Gateway to Global Markets | MEXC - MEXC
Champions Oncology Inc. (CSBR) Q1 2026 Earnings: EPS Falls Sharply Below Estimates Amid Challenging QuarterDividend Increase Stocks - The Legal Advocate
Aurora Innovation, Inc. Files Form 8-K with NASDAQ Listing and Company Details – May 2026 - Minichart
Stronger starts with knowing: HCCH champions a new standard of cancer care - BusinessMirror
EQT Q1 2026 Earnings: Earnings Beat Surprise Amidst Energy Market VolatilityEstimate Revision Count - newsline.com
Champions Oncology (CSBR) Gains 1.59% as Stock Approaches Key Resistance LevelVolume Nodes - The Legal Advocate
Sixth Street Specialty Lending (TSLX) Retreats from Recent Highs: Key Levels to WatchCash Flow Strong Stocks - The Legal Advocate
Japan Stocks Surge to All-Time High on Iran Deal OptimismRevenue Surprise History - The Legal Advocate
Champions Oncology (CSBR) Q1 2026 Earnings: EPS Misses by Wide Margin as Company Posts LossTrading Community Hub - Newser
Champions Oncology, Inc.Common Stock (NQ: CSBR - The Chronicle-Journal
KLIC Q1 2026 Earnings: EPS Surges Past Estimates, Stock AdvancesEarnings Miss Streak - The Legal Advocate
Airbnb (ABNB) Reports Weak Q1 2026 — Cost Pressures Weigh on MarginsRevenue Inflection Point - The Legal Advocate
In Vivo CRO Market Size is Poised to be Valued at USD 11.83 - GlobeNewswire
Intel CEO Lip-Bu Tan Signals Foundry Business Gains Traction Amid Growing Customer InterestROA Comparison - The Legal Advocate
Champions Onc (CSBR) Declines -1.48% Amid Market Weakness 2026-05-19Community Breakout Alerts - Newser
(CSBR) Risk Channels and Responsive Allocation - Stock Traders Daily
Champions Onc (CSBR) Q1 2026 Earnings Miss: EPS $-0.02 vs $0.09 ExpectedSocial Signal Watchlist - Newser
Champions Onc (CSBR) Q1 2026 Results Fall Short — EPS $-0.02, Revenue $N/AShort Squeeze - newser.com
Heartland Express, Inc. 8-K SEC Filing Details for May 14, 2026 – Company Information, Stock, and Compliance - Minichart
Qumulo Champions Olivia Newton-John Cancer Research Institute in New “Imagine” Fundraising Campaign - Business Wire
Cizzle Bio CEO Bill Behnke Participates in National Oncology Commercialization Panel at City of Hope's 25th Ci4CC Summit - PR Newswire
Europe Stocks: Research Stocks from Europe Stock Market - GuruFocus
(CSBR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
How Palmer (PSBD) balances growth with profitability (Mini Rally) 2026-05-07Earnings Miss Risk - The Legal Advocate
Leading Companies Enhancing Their Presence in the Tumor Models Market - openPR.com
Patient-Derived Xenograft (PDX) Models Market (2026-2033) | - openPR.com
Champions Oncology (NASDAQ:CSBR) Shares Cross Below 200-Day Moving AverageWhat's Next? - MarketBeat
Celebration of Champions event held for children affected by cancer - fox5sandiego.com
Liquidity Mapping Around (CSBR) Price Events - Stock Traders Daily
Champions Onc (CSBR) Stock: Is It Forming a Pattern (Market Focus) 2026-04-27MESA MA - newsline.com
Champions Oncology (CSBR) Proxy Filing Summary - Quartr
Champions Oncology (NASDAQ:CSBR) Share Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Champions Oncology Inc Stock (CSBR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):